|
AVASTIN® (bevacizumab) Coverage/ Reimbursement
AVASTIN® (bevacizumab) DIN 02270994
Roche Patient Assistance Program 1-888-748-8926
The Roche Patient Assistance Program is a service for patients who require reimbursement and infusion support for Roche oncology, hematology and rheumatology therapies that are approved by Health Canada. Services include call centre support; financial assistance; reimbursement navigation; infusion coordination (if required); and coordination of distribution and pharmacy services. For more information about the program, please call toll-free 1-888-748-8926. For oncologists or hematologists who wish to print off a Patient Enrollment Form, please click here.
AVASTIN is an eligible benefit through some private insurance plans, and also through some provincial and federal drug programs. The sidebar menu allows you to access specific information on coverage of AVASTIN by private insurance plans, the individual provincial drug benefit/ provincial cancer agency programs and through the federal drug plans. Information includes coverage/ reimbursement criteria and guidelines, special authorization forms, instructions and other resources. Click on the plan or program name to access.
Indication
AVASTIN (bevacizumab) in combination with fluoropyrimidine-based chemotherapy is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum.
Contraindications
AVASTIN (bevacizumab) is contraindicated in patients with known hypersensitivity to:
Any components of the product (for a complete listing, see the Dosage Forms, Composition and Packaging section of the Product Monograph)
Chinese hamster ovary cell products or other recombinant human or humanized antibodies.
AVASTIN is contraindicated in patients with untreated central nervous system (CNS) metastases (see Warnings and Precautions and Adverse Reactions in the Product Monograph).
AVASTIN administration can result in the development of gastrointestinal perforation and wound dehiscence, in some instances resulting in fatality. The incidence of gastrointestinal perforation in patients receiving irinotecan/bolus 5-fluorouracil/leucovorin with AVASTIN was 2%. AVASTIN therapy should be permanently discontinued in patients with gastrointestinal perforation and wound dehiscence requiring medical intervention. AVASTIN therapy should not be initiated for at least 28 days following major surgery or until the surgical wound is fully healed.
Resources for Healthcare Professionals and Patients
Colorectal Cancer Association of Canada Web Site
Cancer Advocacy Coalition Canada Web Site
AVASTIN Product Monograph click on Health Professional Information for the full product monograph
® Trade-Mark of Genentech, Inc., used under license by Hoffmann-La Roche Limited
|
